|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings Paediatrics






Infectious disease 





Public health 





Key Words: diphtheria tetanus pertussis vaccine drug eruptions haemophilus vaccines needles vaccination
| The first 150 words of the full text of this article appear below. |
METHODS
Design:
randomised controlled non-inferiority trial.
Allocation:
concealed.*
Blinding:
blinded (data entry clerks and laboratory staff).*
Follow up period:
34.5 months.
Setting:
18 general practices in 2 primary care trusts in the UK.
Participants:
696 healthy infants due to receive their first immunisation (mean age 62 d, mean weight 5300 g, 52% boys). Exclusion criteria were <37 weeks gestation, birth weight <2500 g, or treatments or conditions that could bias evaluation of immune response.
Intervention:
infants were allocated to vaccination with a 23 gauge, 25 mm needle (wide long needle, n = 240); a 25 gauge, 16 mm needle (narrow short needle, n = 230); or a 25 gauge, 25 mm needle (narrow long needle, n = 226). At 2, 3, and 4 months of age, infants received a combined diphtheria, pertussis, tetanus, and Haemophilusinfluenzae type b vaccine administered into the right thigh and a meningococcal C vaccine into the
Manjula Datta, MD
The Tamilnadu Dr. MGR Medical University
Chennai, India
Related Article
Evid. Based Med. 2007 12: 63-64.
(in )
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |